Working… Menu

NEXUS™ Aortic Arch Stent Graft System First In Man Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02365454
Recruitment Status : Recruiting
First Posted : February 19, 2015
Last Update Posted : September 14, 2018
Information provided by (Responsible Party):
Endospan Ltd.

Brief Summary:
A multicenter, prospective, open-label, non-randomized, interventional clinical study, sponsored by Endospan Ltd. Patients will be followed-up for five years.

Condition or disease Intervention/treatment Phase
Thoracic Aortic Arch Disease Thoracic Aortic Aneurysm Device: Stent Graft Placement (Nexus) Not Applicable

Detailed Description:

The purpose of the study is to evaluate the safety and performance of the Nexus™ Aortic Arch Stent Graft System for the endovascular treatment of thoracic aortic pathologies requiring landing in the Aortic Arch (zone 0, zone 1, zone 2).

The Nexus™ Aortic Arch Stent Graft System is indicated for the endovascular treatment of thoracic aortic pathologies involving the aortic arch (such as aneurisms and dissections). The Nexus™ is intended to exclude the lesion from the blood circulation in patients diagnosed with thoracic aortic pathology and who have appropriate anatomy to accommodate the Nexus™ system in an endovascular procedure.

The primary objectives of the study are to evaluate the safety and performance of the Nexus™ Aortic Arch Aneurysm Stent Graft System.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility Clinical Study to Evaluate the Safety and Performance of the NEXUS™ Aortic Arch Stent Graft System
Study Start Date : August 2014
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Thoracic Aortic Disease Single Arm Study
Thoracic Aortic Disease treated by Stent Graft Placement
Device: Stent Graft Placement (Nexus)

The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via "surgical bypass grafting", either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.

This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system.

Primary Outcome Measures :
  1. Safety: Device related mortality at 30 days post implantation [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Safety: Device related re-intervention within 1 year from implantation [ Time Frame: 1 year ]

Other Outcome Measures:
  1. Performance: Assess the rate of successful disease treatment at 30 days post implantation [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female age ≥ 18.
  • Any Thoracic Aorta pathology requiring landing in the Aortic Arch (zone 0, zone 1, zone2), e.g. aneurysm, dissection, false/Pseudo aneurysm.
  • In patient with a thoracic aneurysm: dilatation of the aortic arch larger than 5.5cm in diameter, or symptomatic aneurysm of the aortic arch, or aortic diameter growth rate > 5mm per 6 months
  • Patient is considered an appropriate candidate for an elective surgery, as evaluated by Physical Status Classification System I, II or III (American Society of Anesthesiologists).
  • Femoral artery diameter as documented by CTA or MRA that allows endovascular access to the diseased site with a 20-22Fr delivery catheter.
  • Access vessels morphology suitable for endovascular repair in terms of tortuosity, calcification and angulation, documented by CTA, MRA.
  • Access vessel (femoral/iliac) diameter > 7 mm
  • Ascending Aorta landing zone length > 30 mm
  • Brachial/Axial Artery diameter > 3 mm
  • Patient understands and is voluntarily willing to participate as evidenced by personally signing the Informed Consent document, and willingness to comply with follow-up schedule

Exclusion Criteria:

  • Female is of childbearing potential
  • Life expectancy of less than 1 year
  • Any medical condition that, according to the investigator's decision, might expose the patient to increased risk by the investigational device or procedure.
  • Acutely ruptured or instable aneurysm or an acute vascular injury due to trauma or infected penetrating ulcers of the aorta.
  • Patient with an increased risk for aneurysm rupture during the procedure.
  • Patient whose arterial access site is not anticipated to accommodate the access of the Nexus™ Delivery System, due to size, tortuosity or hostile groins (scarring, obesity, or previous failed puncture)
  • Patients with severe atherosclerosis or intraluminal thrombus of the aorta or in the BCT
  • Patient is suffering from unstable angina or NYHA classification III and IV and/or ASA classification IV and above.
  • Patient has had a myocardial infarction (MI) or cerebral vascular accident (CVA) within 3 months prior to the planned implantation
  • Patient has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment.
  • Patient with a contraindication to undergo angiography
  • Patient with known sensitivities or allergies to the device materials- Nitinol and polyester
  • Clinical conditions that severely inhibit x-ray visualization of the Aorta.
  • Connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndromes)
  • Patient has history of bleeding diathesis or coagulopathy that may limit the use of dual antiplatelet or anticoagulant therapy by the decision of the investigator
  • Patient has an active systemic infection at the time of the procedure documented by pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11,000 mm3).
  • Patients who have the condition that threatens to infect the stent graft.
  • Acute renal failure; chronic renal failure (excluding dialysis); Creatinine > 2.00 mg/dl or > 182 umol/L
  • Patient underwent major surgery or interventional procedure in the last three months.
  • Any other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, or the procedures and evaluations pre- and post- treatment.
  • Active participation in another clinical trial that is reasonable to conflict with the NexusTM study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02365454

Layout table for location contacts
Contact: Simona Beilin-Nissan +972 9 7884490
Contact: Orly Schwartz +972 9 7884490

Layout table for location information
Faculty Hospital Hradec Kralove Recruiting
Hradec Kralove, Czechia, 500 05
Principal Investigator: Antonin Krajina, Prof. MD         
Vivantes Klinikum Not yet recruiting
Berlin, Germany, 10249
Contact: Hüseyin Ince, Prof. MD         
Contact: Stephan Kische, MD         
Principal Investigator: Hüseyin Ince, Prof. MD         
Sub-Investigator: Stephan Kische, MD         
San Filippo Neri Hospital Recruiting
Rome, Italy, 00135
Principal Investigator: Nicola Mangialardi, Prof. MD         
Sub-Investigator: Sonia Ronchey, MD         
Örebro University Hospital Not yet recruiting
Örebro, Sweden, 7036
Contact: Thomas Larzon, Prof. MD         
Principal Investigator: Thomas Larzon, Prof. MD         
Sub-Investigator: Tal Horer, MD         
Zurich University Hospital Recruiting
Zurich, Switzerland, 8091
Principal Investigator: Mario Lachat, Prof. MD         
Sub-Investigator: Lyubov Chaykovska, MD         
Sponsors and Collaborators
Endospan Ltd.
Layout table for investigator information
Principal Investigator: Mario Lachat, Prof. MD Zurich University Hospital

Layout table for additonal information
Responsible Party: Endospan Ltd. Identifier: NCT02365454     History of Changes
Other Study ID Numbers: CIP004.00
First Posted: February 19, 2015    Key Record Dates
Last Update Posted: September 14, 2018
Last Verified: September 2018
Keywords provided by Endospan Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Aneurysm
Aortic Aneurysm, Thoracic
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases